Compare UPLD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | ALLR |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 19.3M |
| IPO Year | 2014 | 2021 |
| Metric | UPLD | ALLR |
|---|---|---|
| Price | $0.70 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.75 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 351.0K | 212.0K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,767,000.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.77 |
| 52 Week High | $3.90 | $2.35 |
| Indicator | UPLD | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 67.92 |
| Support Level | $0.68 | $0.92 |
| Resistance Level | $0.74 | $1.79 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.99 | 93.98 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.